70,747 Shares in Moderna, Inc. $MRNA Purchased by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. purchased a new position in Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 70,747 shares of the company’s stock, valued at approximately $4,954,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of Moderna during the 1st quarter worth approximately $415,000. NewEdge Advisors LLC grew its position in Moderna by 732.7% in the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after acquiring an additional 10,185 shares during the period. United Services Automobile Association acquired a new position in Moderna during the first quarter worth $230,000. Focus Partners Wealth raised its stake in Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after acquiring an additional 8,706 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Moderna by 5.2% during the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after acquiring an additional 2,410 shares during the period. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the topic of several analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $120.00 target price on shares of Moderna in a report on Wednesday. Morgan Stanley reissued a “neutral” rating on shares of Moderna in a report on Wednesday. Loop Capital set a $135.00 price target on shares of Moderna in a research report on Wednesday. Citigroup upped their price objective on shares of Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $56.56.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company’s stock.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Phase 3 melanoma trial met both key endpoints. Intismeran, Moderna’s individualized mRNA neoantigen therapy, combined with Merck’s Keytruda, significantly improved recurrence-free survival and distant metastasis-free survival versus Keytruda alone in patients with resected, high-risk melanoma. The companies described the results as the first positive late-stage trial for a personalized mRNA cancer vaccine. Merck and Moderna Phase 3 trial announcement
• Positive Sentiment: The results support a broader cancer-treatment opportunity. Analysts and medical commentators said the outcome could validate Moderna’s mRNA platform for treating cancer and potentially open development opportunities across additional tumor types. The vaccine is tailored to mutations in an individual patient’s tumor, offering a potentially differentiated approach to personalized oncology. Moderna and Merck cancer vaccine breakthrough
• Positive Sentiment: Additional developments added to the bullish sentiment. The FDA approved Moderna’s first mRNA-based seasonal influenza vaccine, mFLUSIVA, while William Blair upgraded the stock to “outperform” and Bank of America moved its rating from “underperform” to “neutral.” FDA approval of Moderna mFLUSIVA
• Neutral Sentiment: Investors are awaiting detailed trial data. Moderna and Merck released topline results, but analysts said full efficacy, safety and durability data will be important for assessing regulatory timing and the vaccine’s commercial potential.
• Negative Sentiment: The sharp rally raises execution and valuation risks. The move triggered substantial losses for short sellers and increased options activity, while the stock now reflects much higher expectations for successful approval, manufacturing and adoption. Any disappointing detailed data or regulatory delays could lead to volatility.

Moderna Price Performance

Moderna stock opened at $174.38 on Thursday. The business’s 50-day simple moving average is $64.91 and its 200 day simple moving average is $54.84. The stock has a market cap of $69.62 billion, a price-to-earnings ratio of -21.82 and a beta of 0.91. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. Moderna’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.13) earnings per share. As a group, research analysts anticipate that Moderna, Inc. will post -6.18 earnings per share for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.